ClinicalTrials.gg
CompletedNCT06444178Updated Jul 16, 2025

Assessment of Gastrointestinal Blood Loss After Receiving Aspirin or Aspirin Plus Rivaroxaban, or Aspirin Plus REGN9933, or Aspirin Plus REGN7508 in Healthy Adult Participants

A Phase 1 interventional study of Aspirin and REGN9933 in Healthy Volunteers, sponsored by Regeneron Pharmaceuticals. Completed at 1 site in United Kingdom. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-07-16.

Sponsored by Regeneron Pharmaceuticals · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Apr 2025, 1 year 7 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
224
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 64 studies in Hemorrhage with a site in United Kingdom — 5 open to participants now, 7 under way, 5 of them phase 3. Hemorrhage · United Kingdom.

Enrollment
17th of 48
224 · median 105
Started
2024
with 1 other
Phase 1
3 of 64
none open now
Registered
61st of 64
by date

Among the 64 studies in Hemorrhage with a site in United Kingdom, this one is the 17th largest by enrollment of the 48 interventional ones that give a count, is one of 2 that started in 2024, is one of 3 in phase 1, and was the 61st registered.

Hemorrhage

1,384 studies on the registry are indexed under Hemorrhage; 245 are open to participants now.

Browse Hemorrhage studies →

Open to participants now

5 of the 64 studies in Hemorrhage with a site in United Kingdom are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →

Who these studies take

Of the 171 Hemorrhage studies recruiting now, 109 (64%) set no upper age limit and 41 (24%) stop at 75 or younger; 26 take children under 18; 21 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 64 studies in Hemorrhage with a site in United Kingdom, or all of them as a file.
02

Study summary

This study is researching experimental drugs called REGN9933 and REGN7508 (called "study drugs") and comparing their effects to approved treatments of rivaroxaban and aspirin (called "standard treatments"). Aspirin will be given alone or in combination with the study drugs or the other standard treatments to look at their effects on blood loss in the intestines.

The aim of the study is to see if aspirin alone or the study drugs REGN9933 and REGN7508, when taken with aspirin, cause less minor intestinal bleeding than standard treatments rivaroxaban with aspirin.

The study is looking at several other research questions, including:

  • What side effects may happen from taking the study drug
  • How much study drug is in the blood at different times
  • Whether the body makes antibodies against the study drug (which could make the drug less effective or could lead to side effects)
03

Conditions studied

  • Healthy Volunteers

Browse trials for

Keywords

  • Gastrointestinal (GI) bleeding
  • Fecal occult blood testing (FOBT)
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Key Inclusion Criteria:

  1. between 18.0 and 32.5 kg/m2 (inclusive) at the screening visit
  2. Judged by the investigator to be in good health based on medical history, physical examination, vital sign measurements, and (ECGs) performed at screening and/or prior to administration of initial dose of study treatment
  3. Normal , normal PT, and normal counts at screening period and at the day 1 visit as defined by the local laboratory
  4. values within the normal range, per local laboratory, at the screening and day 1 visits
  5. Negative FOBT at Baseline (visit 2) and visit 3 as defined in the protocol

Key Exclusion Criteria:

  1. History of any major surgical procedure or physical trauma in the last 6 months, in the opinion of the investigator, that may pose a risk to the participant by study participation
  2. Whole blood donation within the previous 56 days or plasma donation within the previous 7 days prior to the screening visit
  3. Hospitalized for any reason within 30 days of the screening visit
  4. Estimated glomerular filtrate rate () of \<60 mL/min/1.73m2 at screening as described in the protocol.
  5. Current smoker or former smoker, including e-cigarettes, who stopped smoking within 12 months prior to the screening visit
  6. History of illicit drug or alcohol abuse within the last 2 years prior to the day 1 visit
  7. Use of any prescription and nonprescription medications or nutritional supplements from approximately 2 weeks or 5 half-lives, as described in protocol
  8. Has elective surgery planned to occur prior to end of study (EOS)

Note: Other Protocol Defined Inclusion/ Exclusion Criteria Apply

Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
224 participants (actual)

Study arms

  • Active comparator
    Arm 1: Aspirin

    Randomized 1:1:1:1

    Drug: Aspirin

  • Experimental
    Arm 2: Aspirin + REGN9933

    Randomized 1:1:1:1

    Drug: Aspirin · Drug: REGN9933

  • Experimental
    Arm 3: Aspirin + REGN7508

    Randomized 1:1:1:1

    Drug: Aspirin · Drug: REGN7508

  • Active comparator
    Arm 4: Aspirin + Rivaroxaban

    Randomized 1:1:1:1

    Drug: Aspirin · Drug: Rivaroxaban

Interventions

06

What researchers measure

Primary outcomes

  1. Change in fecal hemoglobin content (FHC)

    Time frame: Baseline and up to day 22

Secondary outcomes

  1. Incidence of treatment-emergent adverse events (TEAE)

    Time frame: Up to day 100

  2. Severity of TEAE

    Time frame: Up to day 100

  3. Incidence of major bleeding

    Time frame: Up to day 100

  4. Incidence of clinically relevant non-major (CRNM) bleeding

    Time frame: Up to day 100

  5. Concentrations of REGN9933

    Time frame: Up to day 29

  6. Concentrations of REGN7508

    Time frame: Up to day 29

  7. Change in activated partial thromboplastin time (aPTT)

    Time frame: Baseline and up day 29

  8. Change in prothrombin time (PT)

    Time frame: Baseline and up day 29

  9. Incidence of Anti-drug antibody (ADA) to REGN9933

    Time frame: Up to day 29

  10. Titer of ADA to REGN9933

    Time frame: Up to day 29

  11. Incidence of ADA to REGN7508

    Time frame: Up to day 29

  12. Titer of ADA to REGN7508

    Time frame: Up to day 29

07

Study locations

1 site
  • Fortrea Clinical Development
    Leeds, LS11 9EH, United Kingdom
08

References and documents

Individual participant data

Plan to share: Yes — All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

Time frame: When Regeneron has: received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc.) for the product and indication or has globally discontinued development of the product for all indications on or after April 2020 and has no plans for future development made results publicly available (e.g., scientific publication, scientific conference, clinical trial registry) the legal authority to share the data, and ensured the ability to protect participant privacy

Access criteria: Qualified researchers can submit a proposal for access to individual patient or aggregate level data from a Regeneron-sponsored clinical trial through Vivli. Regeneron's Independent Research Request Evaluation Criteria can be found at: https://www.regeneron.com/sites/default/files/Regeneron-External-Data-Sharing-Policy-and-Independent-Research-Request-Evaluation-Criteria.pdf

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2024 to primary completion in Apr 2025, 6 months.

Of 17 phase 1 interventional studies under Hemorrhage, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 42. This study's 6 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
May 30, 2024
First posted
Jun 5, 2024
StartActual
Sep 30, 2024
Primary completionActual
Apr 7, 2025
CompletionActual
Jul 9, 2025
Last update
Jul 16, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 16, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06444178
Responsible party
Sponsor
First posted
Jun 5, 2024
Start date
Sep 30, 2024
Primary completion
Apr 7, 2025
Completion
Jul 9, 2025
Last update
Jul 16, 2025

Study contacts

Clinical Trial Management
study director · Regeneron Pharmaceuticals

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Amrecibart · Cenvacibart

Start the discussion